source
- GSK drops camlipant cough drug after mixed Phase 3 resultsGSK announced it is halting development of camlipant, an experimental chronic cough medicine it acquired in a $2 billion purchase three years ago. The decision follows two Phase 3 trials that show…
- Dimerix acquires Mission's phase-2 ready AKI drug in $292 million dealDimerix announced it has acquired the acute kidney injury candidate MTX652 from Mission Therapeutics in a deal valued at up to $292 million, including a $5 million upfront payment. Mission had com…